- Home
- DKNG vs UTHR Comparison
DKNG vs UTHR Comparison
Compare DKNG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DKNG | UTHR |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8B | 20.3B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | DKNG | UTHR |
|---|---|---|
| Price | $35.18 | $484.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 12 |
| Target Price | $47.71 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 17.5M | 412.1K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | N/A | ★ 26.38 |
| Revenue | ★ $5,458,104,000.00 | $3,128,400,000.00 |
| Revenue This Year | $33.29 | $13.68 |
| Revenue Next Year | $20.08 | $5.63 |
| P/E Ratio | ★ N/A | $18.40 |
| Revenue Growth | ★ 18.50 | 13.50 |
| 52 Week Low | $26.23 | $266.98 |
| 52 Week High | $53.61 | $492.62 |
Technical Indicators
Market Signals| Indicator | DKNG | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 65.15 |
| Support Level | $29.09 | $470.13 |
| Resistance Level | $34.29 | $492.62 |
| Average True Range (ATR) | 1.33 | 10.73 |
| MACD | 0.83 | -0.80 |
| Stochastic Oscillator | 93.09 | 73.30 |
Price Performance
Historical ComparisonAbout DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 28 states and iGaming in five states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.